MedTrace Logo

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

NCT05218096 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-01-09

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams \[mg\], 180 mg) in participants with generalized myasthenia gravis (gMG).

Safety will be monitored throughout the study.

Conditions

Interventions

DRUG

ALXN2050

Oral tablet.

DRUG

Placebo

Oral tablet.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-27
Primary Completion
2023-11-30
Completion
2024-04-03
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Germany
  • Italy
  • Serbia
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05218096 on ClinicalTrials.gov